Brought to you by 
Teva agrees to develop and commercialize Regeneron's fasinumab for pain
20 Oct 2016
Executive Summary
In a deal worth up to $3.6bn, Regeneron Pharmaceuticals Inc. licensed Teva Pharmaceutical Industries Ltd. worldwide rights (except in selected Asian countries) to its nerve growth factor (NGF) antibody fasinumab for osteoarthritis pain (Phase III) and chronic low back pain (Phase II).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva agrees to develop and commercialize Regeneron's fasinumab for pain
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice